Login to Your Account

Port whine? Aduro in toxic rated zone; LADD staggers

By Randy Osborne
Staff Writer

Monday, October 24, 2016

Aduro Biotech Inc. CEO Stephen Isaacs said the company suspects "more of a port issue" than anything else with the latest problem in pancreatic cancer trials with products based on the Listeria-based immunotherapy construct platform.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription